Abstract
New and very expensive forms of radiotherapy, such as intensity-modulated radiation therapy and proton therapy, have taken over the localized prostate cancer market. But is there enough evidence to justify their increased utilization and if so, how can we possibly afford them?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have